Development of an improved rapid enzyme inhibition bioassay with marine and freshwater microalgae using flow cytometry.
A rapid toxicity test based on inhibition of esterase activity in marine and freshwater microalgae (Selenastrum capricornutum, Chlorella sp., Dunaliella tertiolecta, Phaeodactylum tricornutum, Tetraselmis sp., Entomoneis cf. punctulata, Nitzschia cf. paleacea) was developed using flow cytometry. Uptake of fluorescein diacetate (FDA) was optimized for each species by varying the substrate concentration, incubation time, and media pH. Propidium iodide (PI) was utilized to assess membrane integrity. The optimized FDA/PI staining procedure was then used to assess the toxicity of copper in short-term exposures (1-24 h). Esterase activity was a sensitive indicator of copper toxicity in S. capricornutum and E. cf. punctulata. As copper concentrations increased, esterase activity decreased in a concentration-dependent manner. The 3- and 24-h EC50 values (based on mean activity states) were 112 microg Cu L(-1) (95% confidence limits 88-143) and 51 microg Cu L(-1) (95% confidence limits 38-70) for S. capricornutum and 47 microg Cu L(-1) (95% confidence limits 43-51) and 9.1 microg Cu L(-1) (95% confidence limits 7.6-11) for E. cf. punctulata, respectively. This enzyme inhibition endpoint showed similar sensitivity to chronic growth rate inhibition in E. cf. punctulata (48-h and 72-h EC50 values of 17 and 18 microg L(-1), respectively) but was less sensitive compared to growth for S. capricornutum (48-h and 72-h EC50 values of 4.9 and 7.5 microg L(-1), respectively). For the other five species tested, inhibition of FDA fluorescence was relatively insensitive to copper, even at copper concentrations that severely inhibited cell division rate. These short-term bioassays that detect sublethal endpoints may provide a more rapid and cost-effective way of monitoring contaminant impacts in natural waters.
Franklin
N M
NM
Centre for Advanced Analytical Chemistry, CSIRO Energy Technology, Bangor, New South Wales, Australia. natasha.franklin@det.csiro.au
Adams
M S
MS
Stauber
J L
JL
Lim
R P
RP
D001681:Biological Assay / Q000191:economics / Q000379:methods; D003300:Copper / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D004784:Environmental Monitoring; D004950:Esterases / Q000187:drug effects / Q000378:metabolism*; D056890:Eukaryota / Q000187:drug effects / Q000201:enzymology*; D005434:Flow Cytometry; D005452:Fluoresceins / Q000493:pharmacokinetics; D007928:Lethal Dose 50; D015262:Xenobiotics / Q000009:adverse effects*
D005452:Fluoresceins; D015262:Xenobiotics; D003300:Copper; D004950:Esterases; C018506:diacetylfluorescein